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Background: The current study aimed to determine the efficacy immunotherapy
versus the medical treatment in cases of allergic rhinitis-associated migraine.
Patients and Methods: This randomized-controlled study was conducted
in Banha Medical University Hospitals, Egypt in the period 2014-2015. Eligible
patients having both allergic rhinitis and migraine were randomly allocated to
the study group and the control group. For the study group, immunotherapy
was used, and for the control group medical treatment was used. The primary
outcome measure was the IgE level in both groups after the treatment period.
Results: A Forty-one patients were included in the analysis, 20 in the study group
and 21 in the control group. The two groups were comparable regarding the
baseline characteristics.
At the end of the study, there was no significant difference in the IgE level between
groups (p-value 0.288) where it was 18.3 (6.0) & 16.5 (5.1) in the study group
and the control group, respectively. Also, there was no significant difference in
the number of migraine attacks between groups (p-value 0.756) where it was 1.9
(0.7) & 1.8 (0.7) in the study group and the control group, respectively. However,
within-group analysis revealed a highly significant reduction in IgE level and
number of migraine attacks in both groups (p-values < 0.0001).
Conclusions: In conclusion, immunotherapy is as effective as medical treatment
for cases of migraine associated with allergic rhinitis.
Keywords: Allergic rhinitis; migraine; immunotherapy; anti-allergic.
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Background
The prevalences of allergic rhinitis (AR) and migraine are
high in the populations. Therefore, of course, a considerable
proportion of cases suffer from both conditions at the same
time. [1-3]
Many research studies proposed different mediators like
immunoglobulin E (IgE), histamine, vasoactive intestinal
peptide (VIP), tumor necrosis factor-α (TNF-α), interleukin–1
(IL-1) and other mediators in both conditions as a
pathophysiological basis for this association.[4-9]
Different lines of treatment were investigated in each condition
separately using anti-allergic, antileukotriens, other medical
treatment and immunotherapy. However, the literature about
the management of allergic rhinitis associated with migraine
is scarce. [3,10,11]
Therefore, in the current randomized controlled study, we
aimed to compare the effectiveness of immunotherapy and
medical treatment in the treatment of allergic rhinitis and
migraine.
Patients and Methods
This prospective parallel randomized controlled trial was
conducted in Banha University hospital, Egypt, during the period
from December 2014 to December 2015. This study followed
the principles of the Declaration of Helsinki and following the
Medical Research Involving Human Subjects Act (WMO), and
was approved by Institutional Review Board. The purpose of
this study was clearly explained in the Arabic language to all

parents of the subjects before their enrolment to the study, and
an informed consent form was signed by and obtained from all
of those enrolled.
We recruited male and female patients with age from 18-55
years old attending Banha University hospital Egypt having both
allergic rhinitis and migraine.
Full history was taken; present history of allergic rhinitis
(sneezing, rhinorrhea, nasal obstruction, sinusitis, lacrimation
and eye congestion) migraine (± aura, headache attack lasts
for 4 hours two-three days, unilateral, pulsating pain, nausea,
vomiting,
photophobia,
phonophobia,
hemiparaesthetic,
hemiplegic, aphasic) according to the ICHD-3. [12-13]
Randomization and blinding:
Random numbers list was generated by the computer to be used
for the allocation of the participants. Block randomization with
a block size of two was used with 1:1 ratio of immunotherapy
(study) group and traditional treatment (Control) group. The
allocation sequence was concealed from the researchers enrolling
and assessing participants. The study was assessor blinded.
Participants were randomly allocated to the study group and
the control group. Patients of the study group were treated by
immunotherapy. On the other hand, patients of the control group
were treated by the traditional treatment.
Neither the researcher allocating the participants nor the
assessing person knew the decoding of the groups in its relation
to the allocation sequence. Data were collected by a junior pain
resident who was blinded to the study.
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Procedures:
For all patients, comprehensive information about the
participants was collected, including age, gender, and medical
history. Conventional examinations were performed.
Before randomization, the same procedures were applied to both
groups. Blood samples were taken from all patients to measure
the level of the IgE, and skin tests were performed for all patients
to detect allergens (the grading scale is the agreement of the
wheal in mm) less than 4 mm is negative , from 5 to 10 mm
mildly sensitive, from 10 to 15 mm moderately sensitive, and
over 15 mm very sensitive. Patients were asked to stop any antiallergic for 72 hours. Patients were asked for any precipitating
factors and seasonal variation. Patients were asked for the
number of migraine attacks per month.
After randomization, patients in the study group received
immunotherapy scheduled as twice a week. First bottle was
1/1000 concentration, second bottle 1/500, third bottle 1/250,
and the forth bottle 1/125 concentration. The bottle contained
not more than two types of allergen. Aspergillus was given
alone. On the other hand, patients of the control group received
medical treatment in the form of anti-allergic oral fexofenadine
180 once daily before seasons and during attacks ((Telfast,
Sanofi-aventis), for severe cases corticosteroids oral prednisolone
20 mg tab, 100 mg per day for 3 days, reducing the dose by 20
mg every three days (Sloupred, Sanofi-Aventis) , anti-allergic
nasal spray mometasone furoate monohydrate 50 mcg twice
daily (Nasonix, Merck Sharp & Dohme Corp), and alkaline nasal
wash 3-5 times per day.
All patients of both groups were followed up until 6 months.
At the end of the study, all patients were asked for number of
migraine attacks per last month as well as other symptoms of
allergic rhinitis and migraine. Moreover, blood samples were
taken from all patients and IgE levels were measured.
Outcome measures:
The primary outcome measure was the IgE level in both groups

after the treatment period.
Secondary outcome measures were: the number of migraine
attacks on the last month, improvement of symptoms and signs
after the treatment period in both groups as well as the incidence
of any adverse events in both groups.
Statistical analysis and sample size justification:
Taking type I or α error of 5%, type II or β error of 20%, sample
size calculation suggested that a minimum of 16 subjects per
group is required to detect two point differences of 5.1 and
7.3 ng/mL in IgE level with standard deviation of 2.2. . These
numbers were based on a pilot study on 10 participants, five in
each group. We decided to include 25 patients per group to allow
for dropouts.
All statistical tests were made using a significance level of 95%.
SPSS software (Statistical Package for the Social Sciences,
version 20.0, SSPS Inc, Chicago, IL, USA) was used for the
statistical analyses. Data were summarized by mean & standard
deviation or median & interquartile range in the numerical data
according to their distribution and using frequency (count)
and relative frequency (percentage) for categorical data.
Comparisons between quantitative variables were made using
the student t-test and the non-parametric Mann-Whitney test.
For comparing categorical data, Chi-square test was performed.
The Exact test was used instead when the expected frequency
is less than five. P-values less than 0.05 were considered as
statistically significant.
Results
All patients (64 subjects) who came to the center with the
presentation of allergic rhinitis plus migraine were asked to
participate in the study. Sixteen subjects refused to participate.
Enrolled subjects (50) were randomized to the study
(immunotherapy) group and the control (traditional treatment)
group, 25 in each group. Eight patients were excluded after
randomization, four in each group due to lost follow up. The
dispositions of these subjects are shown (Fig. 1).

Fig 1 Consort diagram of statistical analysis of patients

The role of immunotherapy in cases with both allergic rhinitis and migraine, Kazem, et al

Baseline characteristics:
Forty-one patients were included in the analysis, 20 in the
study group and 21 in the control group. There was no
significant difference (p-value > 0.05) between the two
groups regarding the age, gender, seasonal variation, the
presence of aura, occupation, family history or the presence
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of precipitating factors. The average age was 39.9 (SD=10.1)
years in the study group and 33.0 (9.5) years in the control
group (p-value 0.63). The majority of patients in both were
females 60% & 71.4%, for the study group and the control
group, respectively (p-value = 0.333), as shown in Table 1.

Table 1 Baseline characteristics
Study group

Control group

N = 20
Gender

N = 21

p-value

Number

%

Number

%

Female

12

60%

15

71.4%

Male

8

40%

6

28.6%

0.333

Occupation
Employee

10

50%

8

38.1%

Housewife

2

10%

4

19.0%

0.644

Student

5

25%

7

33.3%

Worker

3

15%

2

9.5%

Allergy

17

85%

16

76.2%

0.51

Migraine

18

90%

19

90.5%

0.696

Aura

12

60%

10

47.6%

0.533

Seasonal variation

19

95%

18

85.7%

0.51

INFECTION

7

35%

10

47.6%

0.344

EXERCISE

11

55%

10

47.6%

0.756

Family history

Precipitating factors

DUST

13

65%

13

61.9%

0.95

HYPOGLASEMA

13

65%

13

61.9%

1

SLEEP

14

70%

13

61.9%

0.746

Mean (SD)
Age, year

Median (IQR)

Mean (SD)

Median (IQR)

40 (20)

33.0 (9.5)

35 (20)

39.9 (10.1)

Allergy skin test:
There was insignificant difference between the study group
and the control group with regard the type of allergen

0.63

detected (p = 0.967). Pollen and dust were the most
prevalent allergen in both groups (more than 70%) followed
by rice straw, wool and aspergillus, as shown in Table 2.

Table 2 Allergic skin test
Study group

Control group

N = 20

N = 21

p-value

Number

%

Number

%

Pollen

15

75%

16

76.2%

Dust

16

80%

15

71.4%

Rice straw

12

60%

12

57.1%

Wool

12

60%

11

52.4%

Asprigillus

4

20%

5

23.8%

0.967
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IgE test and number of migraine attacks before and
after treatment:
At the start of the study and before treatment, there was no
significant difference in the the level of IgE between groups
(p-value 0.957), where it was 23.3 (4.6) & 23.2 (4.6) in
the study group and the control group, respectively. Also,
at the start of the study and before treatment, there was
no significant difference in the number of migraine attacks
between groups (p-value 0.221) where it was 4.7 (1.2) & 4.9
(1.3) in the study group and the control group, respectively.

there was no significant difference in the level of IgE between
groups (p-value 0.288), where it was 18.3 (6.0) & 16.5 (5.1)
in the study group and the control group, respectively. Also,
there was no significant difference in the number of migraine
attacks between groups (p-value 756) where it was 1.9
(0.7) & 1.8 (0.7) in the study group and the control group,
respectively.
However, within-group analysis revealed a highly significant
reduction in IgE level and number of migraine attacks in both
groups (p-values < 0.0001), as shown in Table 3.

At the end of the study and after treatment period, also,

Table 3A IgE and migraine attacks between groups analysis
Study group

Control group

N = 20

p-value

N = 21

Mean

Median

Mean

Median

(SD)

(IQR)

(SD)

(IQR)

IgE before treatment ng/mL

23.3 (4.6)

22.7 (6.4)

23.2 (4.6)

22 (6.4)

0.957

IgE after treatment

18.3 (6.0)

18.6 (7.25)

16.5 (5.1)

17.9 (6.85)

0.288

Number of migraine attacks per month before treatment

4.7 (1.2)

4 (2)

4.9 (1.3)

5 (2)

0.221

Number of migraine attacks per month after treatment

1.9 (0.7)

2 (1)

1.8 (0.7)

2 (1.3)

0.756

Table 3B IgE and migraine attacks within group analysis
Mean difference (SD)

95% Confidence Interval of the Difference

p-value

Immunotherapy group
IgE, ng/mL

4.94 (2.66)

3.73-6.15

< 0.001

Migraine attacks, number per month

2.81 (0.91)

2.39-2.32

< 0.001

IgE, ng/mL

6.72 (4.38)

4.73-8.71

< 0.001

Migraine attacks

3.07 (1.06)

2.59-3.56

< 0.001

Medical treatment group

Discussion
This randomized placebo-controlled trial was conducted to
compare the immunotherapy to traditional medical treatment
as alternative ways for the management of allergic rhinitis
with migraine cases. The results if our study showed that
there was no significant difference in the level of IgE between
both groups. Also, at the end of the study there was no
significant difference in the number of migraine attacks
between groups. However, within-group analysis revealed
a highly significant reduction in IgE level and number of
migraine attacks in both groups.
In consistence with the results of our study, many researchers
showed that immunotherapy decreases the frequency of the
headache attacks in those patients with an atopic headache.
[11,14-16] Mansfield et al. reported that 40% of migraineurs
were atopic for specific food allergens as proved by skin prick
tests. After avoidance of the identified foods, 69% of those
cases had at least a 66% reduction in the frequency of the
headache attacks compared with baseline. [17]
Immunotherapy (e.g., allergy injections) can produce

tolerance to specific allergens by modifying the cytokine
responses of T-helper cells, and the induction of IgG and IgA
antibodies that can block IgE binding to mast cells. [18]
In our study, all cases received immunotherapy have more
frequent migraine attacks at the first month, however, after
the first month the number of attacks decreased significantly.
The results of our study showed that the medical treatment
was as effective as the immunotherapy in management
of allergic rhinitis with migraine. The role of anti-allergic
therapy in migraine was proposed by Manfield in 1990. [19]
However, no documented benefit from H1 or H2 blockers
in preventing migraine headaches was established. The
authors reported that anti-allergic might potentiate the pain
relief when combined with a narcotic agent. [19] Thus,
cinnarizine, an L-type calcium channel blocker with antiallergic properties, has shown promise in the prophylaxis for
migraine. [20] Furthermore, montelukast has been studied
in those cases by Carvalho et al. [21] who reported that
24-week treatment decreased reported asthma attacks and
significantly decreased the headache frequency in patients
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with asthma and migraine. Another open-label study showed
a promise in using montelukast in prevention. [22] However,
further studies have failed to show a benefit. [23]
Conclusions
In conclusion, immunotherapy is as effective as medical
treatment for cases of migraine associated with allergic
rhinitis. Further multicentre randomized controlled study with
large sample size is recommended to emphasize the results
of this study.
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